Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 954 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Obstructive Airway Disease Clear all
Completed Phase 3 Interventional Results available

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

NCT00419744
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
92
States / cities
Jasper, Alabama • Mobile, Alabama • Tucson, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Jul 22, 2026, 5:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acoustic Waveform Respiratory Evaluation

NCT06512064
View directory record Official record
Conditions
Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
Interventions
AWARE
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 22, 2026, 5:56 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verekitug, Placebo
Drug · Other
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Bakersfield, California • Encino, California • Lomita, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Phase 4 Interventional

Chronic Obstructive Pulmonary Disease Endpoints Study

NCT00358358
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg, Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Combined Illness Management and Psychotherapy in Treating Depressed Elders

NCT01337726
View directory record Official record
Conditions
Depression, Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Combined Psychotherapy and Illness Management, Illness Management Only
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
55 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 22, 2026, 5:56 AM EDT
Terminated Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

NCT01972776
View directory record Official record
Conditions
COPD
Interventions
QBM076, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Jul 22, 2026, 5:56 AM EDT
Completed No phase listed Observational Results available

Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease

NCT00595114
View directory record Official record
Conditions
Asthma, Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Jul 22, 2026, 5:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

NCT04722835
View directory record Official record
Conditions
Copd, Smoking, Tobacco Use
Interventions
Bronchoscopy with Bronchoalveolar Lavage (BAL)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 5:56 AM EDT
Recruiting Not applicable Interventional

Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF

NCT05934565
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Heart Failure
Interventions
Mindful Steps
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 22, 2026, 5:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints

NCT00292552
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Novel endpoint determination
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
2,747 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
20
States / cities
Phoenix, Arizona • Rancho Mirage, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AQX-1125 in Unstable COPD

NCT01954628
View directory record Official record
Conditions
COPD
Interventions
AQX-1125, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jul 22, 2026, 5:56 AM EDT
Completed No phase listed Observational

Screening Evaluation for Studies of Chronic Obstructive Pulmonary Disease (COPD)

NCT00889447
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 100 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

Study in Subjects Greater Than 40 Years of Age With COPD

NCT00507234
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
formoterol fumarate inhalation solution
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Jul 22, 2026, 5:56 AM EDT
Recruiting Phase 3 Interventional

Multi-Center Clean Air Randomized Controlled Trial in COPD

NCT06376994
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Air cleaner, Sham air cleaner
Device
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
40 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

NCT01323660
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125, GSK573719 62.5, GW642444 25, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Jul 22, 2026, 5:56 AM EDT
Terminated Not applicable Interventional

Effects of High Flow Nasal Cannula on Sputum Clearance in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT04217746
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD Exacerbation, Airflow Obstruction
Interventions
High Flow Nasal Cannula
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies

NCT03244059
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Emphysema
Interventions
Belimumab, Placebo
Biological · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

NCT02772159
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 22, 2026, 5:56 AM EDT
Terminated No phase listed Observational

Acute Exacerbation of COPD and Physical Activity - Preliminary Study

NCT01871246
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jul 22, 2026, 5:56 AM EDT
Active, not recruiting Not applicable Interventional

Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease

NCT05119556
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Video Telehealth Pulmonary Rehabilitation
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Chicago, Illinois • Iowa City, Iowa + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jul 22, 2026, 5:56 AM EDT
Terminated Phase 2 Interventional

Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease

NCT00181272
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Jul 22, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

NCT00206154
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
143
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Jul 22, 2026, 5:56 AM EDT
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 22, 2026, 5:56 AM EDT